img

Global Parkinson’s Disease Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Parkinson’s Disease Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors.
Due to the COVID-19 pandemic, the global Parkinson’s Disease Therapeutics market size was US$ 2337.8 million in 2022 and is forecast to a readjusted size of US$ 3533.7 million by 2034 with a CAGR of 6.0% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Oral accounting for % of the Parkinson’s Disease Therapeutics global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The global key companies of Parkinson’s Disease Therapeutics include Abbvie, Biogen, Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline, H. Lundbeck A/S, Impax Labs, Newron Pharmaceuticals SpA and Novartis AG, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Parkinson’s Disease Therapeutics market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Parkinson’s Disease Therapeutics landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Parkinson’s Disease Therapeutics market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Parkinson’s Disease Therapeutics market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Parkinson’s Disease Therapeutics market. Readers of the report can become informed about current and future trends of the global Parkinson’s Disease Therapeutics market and how they will impact market growth during the forecast period.



By Company


Abbvie
Biogen
Boehringer Ingelheim GmbH
F. Hoffman-La Roche
GlaxoSmithKline
H. Lundbeck A/S
Impax Labs
Newron Pharmaceuticals SpA
Novartis AG
Orion Corporation
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Segment by Type
Oral
Transdermal
Subcutaneous
Intestinal Infusion

Segment by Application


Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Parkinson’s Disease Therapeutics in global and regional level.
Chapter 3Detailed analysis of Parkinson’s Disease Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinson’s Disease Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Parkinson’s Disease Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Oral
1.2.3 Transdermal
1.2.4 Subcutaneous
1.2.5 Intestinal Infusion
1.3 Market by Application
1.3.1 Global Parkinson’s Disease Therapeutics Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Parkinson’s Disease Therapeutics Market Size (2018-2034)
2.2 Parkinson’s Disease Therapeutics Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Parkinson’s Disease Therapeutics Market Size by Region (2018-2024)
2.4 Global Parkinson’s Disease Therapeutics Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Parkinson’s Disease Therapeutics Countries Ranking by Market Size
3 Parkinson’s Disease Therapeutics Competitive by Company
3.1 Global Parkinson’s Disease Therapeutics Revenue by Players
3.1.1 Global Parkinson’s Disease Therapeutics Revenue by Players (2018-2024)
3.1.2 Global Parkinson’s Disease Therapeutics Market Share by Players (2018-2024)
3.2 Global Parkinson’s Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Parkinson’s Disease Therapeutics Revenue
3.4 Global Parkinson’s Disease Therapeutics Market Concentration Ratio
3.4.1 Global Parkinson’s Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Parkinson’s Disease Therapeutics Revenue in 2022
3.5 Global Key Players of Parkinson’s Disease Therapeutics Head office and Area Served
3.6 Global Key Players of Parkinson’s Disease Therapeutics, Product and Application
3.7 Global Key Players of Parkinson’s Disease Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Parkinson’s Disease Therapeutics Breakdown Data by Type
4.1 Global Parkinson’s Disease Therapeutics Historic Revenue by Type (2018-2024)
4.2 Global Parkinson’s Disease Therapeutics Forecasted Revenue by Type (2024-2034)
5 Global Parkinson’s Disease Therapeutics Breakdown Data by Application
5.1 Global Parkinson’s Disease Therapeutics Historic Market Size by Application (2018-2024)
5.2 Global Parkinson’s Disease Therapeutics Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Parkinson’s Disease Therapeutics Revenue by Company (2021-2024)
6.2 North America Parkinson’s Disease Therapeutics Revenue by Type (2018-2034)
6.3 North America Parkinson’s Disease Therapeutics Revenue by Application (2018-2034)
6.4 North America Parkinson’s Disease Therapeutics Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Parkinson’s Disease Therapeutics Revenue by Company (2021-2024)
7.2 Europe Parkinson’s Disease Therapeutics Revenue by Type (2018-2034)
7.3 Europe Parkinson’s Disease Therapeutics Revenue by Application (2018-2034)
7.4 Europe Parkinson’s Disease Therapeutics Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Parkinson’s Disease Therapeutics Revenue by Company (2021-2024)
8.2 Asia Pacific Parkinson’s Disease Therapeutics Revenue by Type (2018-2034)
8.3 Asia Pacific Parkinson’s Disease Therapeutics Revenue by Application (2018-2034)
8.4 Asia Pacific Parkinson’s Disease Therapeutics Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Parkinson’s Disease Therapeutics Revenue by Company (2021-2024)
9.2 Latin America Parkinson’s Disease Therapeutics Revenue by Type (2018-2034)
9.3 Latin America Parkinson’s Disease Therapeutics Revenue by Application (2018-2034)
9.4 Latin America Parkinson’s Disease Therapeutics Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Company (2021-2024)
10.2 Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Type (2018-2034)
10.3 Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Application (2018-2034)
10.4 Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Abbvie
11.1.1 Abbvie Company Details
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Parkinson’s Disease Therapeutics Products and Services
11.1.4 Abbvie Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.1.5 Abbvie Parkinson’s Disease Therapeutics SWOT Analysis
11.1.6 Abbvie Recent Development
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Parkinson’s Disease Therapeutics Products and Services
11.2.4 Biogen Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.2.5 Biogen Parkinson’s Disease Therapeutics SWOT Analysis
11.2.6 Biogen Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Details
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Products and Services
11.3.4 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.3.5 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics SWOT Analysis
11.3.6 Boehringer Ingelheim GmbH Recent Development
11.4 F. Hoffman-La Roche
11.4.1 F. Hoffman-La Roche Company Details
11.4.2 F. Hoffman-La Roche Business Overview
11.4.3 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Products and Services
11.4.4 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.4.5 F. Hoffman-La Roche Parkinson’s Disease Therapeutics SWOT Analysis
11.4.6 F. Hoffman-La Roche Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Parkinson’s Disease Therapeutics Products and Services
11.5.4 GlaxoSmithKline Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.5.5 GlaxoSmithKline Parkinson’s Disease Therapeutics SWOT Analysis
11.5.6 GlaxoSmithKline Recent Development
11.6 H. Lundbeck A/S
11.6.1 H. Lundbeck A/S Company Details
11.6.2 H. Lundbeck A/S Business Overview
11.6.3 H. Lundbeck A/S Parkinson’s Disease Therapeutics Products and Services
11.6.4 H. Lundbeck A/S Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.6.5 H. Lundbeck A/S Parkinson’s Disease Therapeutics SWOT Analysis
11.6.6 H. Lundbeck A/S Recent Development
11.7 Impax Labs
11.7.1 Impax Labs Company Details
11.7.2 Impax Labs Business Overview
11.7.3 Impax Labs Parkinson’s Disease Therapeutics Products and Services
11.7.4 Impax Labs Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.7.5 Impax Labs Parkinson’s Disease Therapeutics SWOT Analysis
11.7.6 Impax Labs Recent Development
11.8 Newron Pharmaceuticals SpA
11.8.1 Newron Pharmaceuticals SpA Company Details
11.8.2 Newron Pharmaceuticals SpA Business Overview
11.8.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Products and Services
11.8.4 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.8.5 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics SWOT Analysis
11.8.6 Newron Pharmaceuticals SpA Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Details
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Parkinson’s Disease Therapeutics Products and Services
11.9.4 Novartis AG Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.9.5 Novartis AG Parkinson’s Disease Therapeutics SWOT Analysis
11.9.6 Novartis AG Recent Development
11.10 Orion Corporation
11.10.1 Orion Corporation Company Details
11.10.2 Orion Corporation Business Overview
11.10.3 Orion Corporation Parkinson’s Disease Therapeutics Products and Services
11.10.4 Orion Corporation Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.10.5 Orion Corporation Parkinson’s Disease Therapeutics SWOT Analysis
11.10.6 Orion Corporation Recent Development
11.11 Teva Pharmaceutical Industries Ltd.
11.11.1 Teva Pharmaceutical Industries Ltd. Company Details
11.11.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.11.3 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Products and Services
11.11.4 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.11.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.12 UCB S.A.
11.12.1 UCB S.A. Company Details
11.12.2 UCB S.A. Business Overview
11.12.3 UCB S.A. Parkinson’s Disease Therapeutics Products and Services
11.12.4 UCB S.A. Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.12.5 UCB S.A. Recent Development
11.13 Livzon Pharmaceutical
11.13.1 Livzon Pharmaceutical Company Details
11.13.2 Livzon Pharmaceutical Business Overview
11.13.3 Livzon Pharmaceutical Parkinson’s Disease Therapeutics Products and Services
11.13.4 Livzon Pharmaceutical Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.13.5 Livzon Pharmaceutical Recent Development
11.14 Haisco Pharmaceutical
11.14.1 Haisco Pharmaceutical Company Details
11.14.2 Haisco Pharmaceutical Business Overview
11.14.3 Haisco Pharmaceutical Parkinson’s Disease Therapeutics Products and Services
11.14.4 Haisco Pharmaceutical Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.14.5 Haisco Pharmaceutical Recent Development
11.15 Jingxin Pharmaceutical
11.15.1 Jingxin Pharmaceutical Company Details
11.15.2 Jingxin Pharmaceutical Business Overview
11.15.3 Jingxin Pharmaceutical Parkinson’s Disease Therapeutics Products and Services
11.15.4 Jingxin Pharmaceutical Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.15.5 Jingxin Pharmaceutical Recent Development
11.16 Dongcheng Biochemicals
11.16.1 Dongcheng Biochemicals Company Details
11.16.2 Dongcheng Biochemicals Business Overview
11.16.3 Dongcheng Biochemicals Parkinson’s Disease Therapeutics Products and Services
11.16.4 Dongcheng Biochemicals Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024)
11.16.5 Dongcheng Biochemicals Recent Development
12 Parkinson’s Disease Therapeutics Market Dynamics
12.1 Parkinson’s Disease Therapeutics Industry Trends
12.2 Parkinson’s Disease Therapeutics Market Drivers
12.3 Parkinson’s Disease Therapeutics Market Challenges
12.4 Parkinson’s Disease Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Parkinson’s Disease Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Oral
Table 3. Key Players of Transdermal
Table 4. Key Players of Subcutaneous
Table 5. Key Players of Intestinal Infusion
Table 6. Global Parkinson’s Disease Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 7. Global Parkinson’s Disease Therapeutics Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 8. Global Parkinson’s Disease Therapeutics Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Parkinson’s Disease Therapeutics Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 10. Global Parkinson’s Disease Therapeutics Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 11. Global Parkinson’s Disease Therapeutics Revenue by Players (2018-2024) & (US$ Million)
Table 12. Global Parkinson’s Disease Therapeutics Market Share by Players (2018-2024)
Table 13. Global Top Parkinson’s Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinson’s Disease Therapeutics as of 2022)
Table 14. Ranking of Global Top Parkinson’s Disease Therapeutics Companies by Revenue (US$ Million) in 2022
Table 15. Global 5 Largest Players Market Share by Parkinson’s Disease Therapeutics Revenue (CR5 and HHI) & (2018-2024)
Table 16. Global Key Players of Parkinson’s Disease Therapeutics, Headquarters and Area Served
Table 17. Global Key Players of Parkinson’s Disease Therapeutics, Product and Application
Table 18. Global Key Players of Parkinson’s Disease Therapeutics, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Parkinson’s Disease Therapeutics Market Size by Type (2018-2024) & (US$ Million)
Table 21. Global Parkinson’s Disease Therapeutics Revenue Market Share by Type (2018-2024)
Table 22. Global Parkinson’s Disease Therapeutics Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 23. Global Parkinson’s Disease Therapeutics Revenue Market Share by Type (2024-2034)
Table 24. Global Parkinson’s Disease Therapeutics Market Size by Application (2018-2024) & (US$ Million)
Table 25. Global Parkinson’s Disease Therapeutics Revenue Market Share by Application (2018-2024)
Table 26. Global Parkinson’s Disease Therapeutics Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 27. Global Parkinson’s Disease Therapeutics Revenue Market Share by Application (2024-2034)
Table 28. North America Parkinson’s Disease Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 29. North America Parkinson’s Disease Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 30. North America Parkinson’s Disease Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 31. North America Parkinson’s Disease Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 32. North America Parkinson’s Disease Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 33. North America Parkinson’s Disease Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 34. North America Parkinson’s Disease Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 35. North America Parkinson’s Disease Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 36. Europe Parkinson’s Disease Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 37. Europe Parkinson’s Disease Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 38. Europe Parkinson’s Disease Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 39. Europe Parkinson’s Disease Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 40. Europe Parkinson’s Disease Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 41. Europe Parkinson’s Disease Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 42. Europe Parkinson’s Disease Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 43. Europe Parkinson’s Disease Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 44. Asia Pacific Parkinson’s Disease Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 45. Asia Pacific Parkinson’s Disease Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 46. Asia Pacific Parkinson’s Disease Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 47. Asia Pacific Parkinson’s Disease Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 48. Asia Pacific Parkinson’s Disease Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 49. Asia-Pacific Parkinson’s Disease Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 50. Asia Pacific Parkinson’s Disease Therapeutics Revenue by Region (2018-2024) & (US$ Million)
Table 51. Asia Pacific Parkinson’s Disease Therapeutics Revenue by Region (2024-2034) & (US$ Million)
Table 52. Latin America Parkinson’s Disease Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 53. Latin America Parkinson’s Disease Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 54. Latin America Parkinson’s Disease Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 55. Latin America Parkinson’s Disease Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 56. Latin America Parkinson’s Disease Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 57. Latin America Parkinson’s Disease Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 58. Latin America Parkinson’s Disease Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 59. Latin America Parkinson’s Disease Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 60. Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Company (2021-2024) & (US$ Million)
Table 61. Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Parkinson’s Disease Therapeutics Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 66. Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Country (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Parkinson’s Disease Therapeutics Revenue by Country (2024-2034) & (US$ Million)
Table 68. Abbvie Company Details
Table 69. Abbvie Business Overview
Table 70. Abbvie Parkinson’s Disease Therapeutics Product and Services
Table 71. Abbvie Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 72. Abbvie Parkinson’s Disease Therapeutics SWOT Analysis
Table 73. Abbvie Recent Development
Table 74. Biogen Company Details
Table 75. Biogen Business Overview
Table 76. Biogen Parkinson’s Disease Therapeutics Product and Services
Table 77. Biogen Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 78. Biogen Parkinson’s Disease Therapeutics SWOT Analysis
Table 79. Biogen Recent Development
Table 80. Boehringer Ingelheim GmbH Company Details
Table 81. Boehringer Ingelheim GmbH Business Overview
Table 82. Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Product and Services
Table 83. Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 84. Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics SWOT Analysis
Table 85. Boehringer Ingelheim GmbH Recent Development
Table 86. F. Hoffman-La Roche Company Details
Table 87. F. Hoffman-La Roche Business Overview
Table 88. F. Hoffman-La Roche Parkinson’s Disease Therapeutics Product and Services
Table 89. F. Hoffman-La Roche Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 90. F. Hoffman-La Roche Parkinson’s Disease Therapeutics SWOT Analysis
Table 91. F. Hoffman-La Roche Recent Development
Table 92. GlaxoSmithKline Company Details
Table 93. GlaxoSmithKline Business Overview
Table 94. GlaxoSmithKline Parkinson’s Disease Therapeutics Product and Services
Table 95. GlaxoSmithKline Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 96. GlaxoSmithKline Parkinson’s Disease Therapeutics SWOT Analysis
Table 97. GlaxoSmithKline Recent Development
Table 98. H. Lundbeck A/S Company Details
Table 99. H. Lundbeck A/S Business Overview
Table 100. H. Lundbeck A/S Parkinson’s Disease Therapeutics Product and Services
Table 101. H. Lundbeck A/S Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 102. H. Lundbeck A/S Parkinson’s Disease Therapeutics SWOT Analysis
Table 103. H. Lundbeck A/S Recent Development
Table 104. Impax Labs Company Details
Table 105. Impax Labs Business Overview
Table 106. Impax Labs Parkinson’s Disease Therapeutics Product and Services
Table 107. Impax Labs Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 108. Impax Labs Parkinson’s Disease Therapeutics SWOT Analysis
Table 109. Impax Labs Recent Development
Table 110. Newron Pharmaceuticals SpA Company Details
Table 111. Newron Pharmaceuticals SpA Business Overview
Table 112. Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Product and Services
Table 113. Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 114. Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics SWOT Analysis
Table 115. Newron Pharmaceuticals SpA Recent Development
Table 116. Novartis AG Company Details
Table 117. Novartis AG Business Overview
Table 118. Novartis AG Parkinson’s Disease Therapeutics Product and Services
Table 119. Novartis AG Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 120. Novartis AG Parkinson’s Disease Therapeutics SWOT Analysis
Table 121. Novartis AG Recent Development
Table 122. Orion Corporation Company Details
Table 123. Orion Corporation Business Overview
Table 124. Orion Corporation Parkinson’s Disease Therapeutics Product and Services
Table 125. Orion Corporation Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 126. Orion Corporation Parkinson’s Disease Therapeutics SWOT Analysis
Table 127. Orion Corporation Recent Development
Table 128. Teva Pharmaceutical Industries Ltd. Company Details
Table 129. Teva Pharmaceutical Industries Ltd. Business Overview
Table 130. Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Product and Services
Table 131. Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 132. Teva Pharmaceutical Industries Ltd. Recent Development
Table 133. UCB S.A. Company Details
Table 134. UCB S.A. Business Overview
Table 135. UCB S.A. Parkinson’s Disease Therapeutics Product and Services
Table 136. UCB S.A. Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 137. UCB S.A. Recent Development
Table 138. Livzon Pharmaceutical Company Details
Table 139. Livzon Pharmaceutical Business Overview
Table 140. Livzon Pharmaceutical Parkinson’s Disease Therapeutics Product and Services
Table 141. Livzon Pharmaceutical Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 142. Livzon Pharmaceutical Recent Development
Table 143. Haisco Pharmaceutical Company Details
Table 144. Haisco Pharmaceutical Business Overview
Table 145. Haisco Pharmaceutical Parkinson’s Disease Therapeutics Product and Services
Table 146. Haisco Pharmaceutical Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 147. Haisco Pharmaceutical Recent Development
Table 148. Jingxin Pharmaceutical Company Details
Table 149. Jingxin Pharmaceutical Business Overview
Table 150. Jingxin Pharmaceutical Parkinson’s Disease Therapeutics Product and Services
Table 151. Jingxin Pharmaceutical Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 152. Jingxin Pharmaceutical Recent Development
Table 153. Dongcheng Biochemicals Company Details
Table 154. Dongcheng Biochemicals Business Overview
Table 155. Dongcheng Biochemicals Parkinson’s Disease Therapeutics Product and Services
Table 156. Dongcheng Biochemicals Parkinson’s Disease Therapeutics Revenue in Parkinson’s Disease Therapeutics Business (2018-2024) & (US$ Million)
Table 157. Dongcheng Biochemicals Recent Development
Table 158. Parkinson’s Disease Therapeutics Market Trends
Table 159. Parkinson’s Disease Therapeutics Market Drivers
Table 160. Parkinson’s Disease Therapeutics Market Challenges
Table 161. Parkinson’s Disease Therapeutics Market Restraints
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Parkinson’s Disease Therapeutics Product Picture
Figure 2. Global Parkinson’s Disease Therapeutics Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Parkinson’s Disease Therapeutics Market Share by Type: 2022 VS 2034
Figure 4. Oral Features
Figure 5. Transdermal Features
Figure 6. Subcutaneous Features
Figure 7. Intestinal Infusion Features
Figure 8. Global Parkinson’s Disease Therapeutics Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 9. Global Parkinson’s Disease Therapeutics Market Share by Application: 2022 VS 2034
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. Others
Figure 13. Parkinson’s Disease Therapeutics Report Years Considered
Figure 14. Global Parkinson’s Disease Therapeutics Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Parkinson’s Disease Therapeutics Market Size 2018-2034 (US$ Million)
Figure 16. Global Parkinson’s Disease Therapeutics Market Size Market Share by Region: 2022 VS 2034
Figure 17. Global Parkinson’s Disease Therapeutics Revenue Market Share by Region in 2018 VS 2022
Figure 18. Global Parkinson’s Disease Therapeutics Revenue Market Share Forecast by Region (2024-2034)
Figure 19. Global Top 10 Parkinson’s Disease Therapeutics Countries Ranking by Market Size (US$ Million) in 2022
Figure 20. Global Parkinson’s Disease Therapeutics Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 21. Global Parkinson’s Disease Therapeutics Market Share by Players in 2022
Figure 22. Global Top Parkinson’s Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinson’s Disease Therapeutics as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Parkinson’s Disease Therapeutics Revenue in 2022
Figure 24. North America Parkinson’s Disease Therapeutics Revenue Market Share by Company in 2022
Figure 25. North America Parkinson’s Disease Therapeutics Revenue Market Share by Type (2018-2034)
Figure 26. North America Parkinson’s Disease Therapeutics Revenue Market Share by Application (2018-2034)
Figure 27. North America Parkinson’s Disease Therapeutics Revenue Share by Country (2018-2034)
Figure 28. United States Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 29. Canada Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 30. Europe Parkinson’s Disease Therapeutics Revenue Market Share by Company in 2022
Figure 31. Europe Parkinson’s Disease Therapeutics Revenue Market Share by Type (2018-2034)
Figure 32. Europe Parkinson’s Disease Therapeutics Revenue Market Share by Application (2018-2034)
Figure 33. Europe Parkinson’s Disease Therapeutics Revenue Share by Country (2018-2034)
Figure 34. Germany Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 35. France Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 36. U.K. Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 37. Italy Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 38. Russia Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Parkinson’s Disease Therapeutics Revenue Market Share by Company in 2022
Figure 40. Asia Pacific Parkinson’s Disease Therapeutics Revenue Market Share by Type (2018-2034)
Figure 41. Asia Pacific Parkinson’s Disease Therapeutics Revenue Market Share by Application (2018-2034)
Figure 42. Asia Pacific Parkinson’s Disease Therapeutics Revenue Share by Region (2018-2034)
Figure 43. China Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 44. Japan Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 45. South Korea Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 46. India Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 47. Australia Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 48. China Taiwan Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 49. Indonesia Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 50. Thailand Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 51. Malaysia Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America Parkinson’s Disease Therapeutics Revenue Market Share by Company in 2022
Figure 53. Latin America Parkinson’s Disease Therapeutics Revenue Market Share by Type (2018-2034)
Figure 54. Latin America Parkinson’s Disease Therapeutics Revenue Market Share by Application (2018-2034)
Figure 55. Latin America Parkinson’s Disease Therapeutics Revenue Share by Country (2018-2034)
Figure 56. Mexico Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Parkinson’s Disease Therapeutics Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Parkinson’s Disease Therapeutics Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Parkinson’s Disease Therapeutics Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Parkinson’s Disease Therapeutics Revenue Share by Country (2018-2034)
Figure 63. Turkey Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 65. UAE Parkinson’s Disease Therapeutics Revenue (2018-2034) & (US$ Million)
Figure 66. Abbvie Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 67. Biogen Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 68. Boehringer Ingelheim GmbH Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 69. F. Hoffman-La Roche Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 70. GlaxoSmithKline Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 71. H. Lundbeck A/S Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 72. Impax Labs Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 73. Newron Pharmaceuticals SpA Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 74. Novartis AG Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 75. Orion Corporation Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 76. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 77. UCB S.A. Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 78. Livzon Pharmaceutical Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 79. Haisco Pharmaceutical Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 80. Jingxin Pharmaceutical Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 81. Dongcheng Biochemicals Revenue Growth Rate in Parkinson’s Disease Therapeutics Business (2018-2024)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed